{"id":"https://genegraph.clinicalgenome.org/r/a0504490-d6e8-4eb3-ab5a-806f28408a1cv3.1","type":"EvidenceStrengthAssertion","dc:description":["*HNRNPDL* belongs to the subfamily of ubiquitously expressed heterogeneous nuclear ribonucleoproteins and encodes the protein heterogeneous nuclear ribonucleoprotein D like. Ribonucleoproteins bind to pre-mRNA and are involved in splicing and nuclear export. The *HNRNPDL* gene contains nine exons and eight introns, and three isoforms are produced by alternate splicing. The domain content of these isoforms differs, and they show distinct subcellular localization and properties relating to solubility, propensity to aggregation, and phase separation (PMID: 31995753). Isoform 2, which is prone to aggregation due to the loss of the N-terminal intrinsically disordered region (IDR) but retention of the C-terminal IDR, or prion-like domain, is most highly expressed in tissues. *HNRNPDL* was first reported in relation to autosomal dominant limb girdle muscular dystrophy (LGMD; includes LGMD1G/LGMDD3) in 2014 (Vieira et al, PMID: 24647604), although linkage analysis implicated the locus in 2004 (PMID: 15367920). Features observed in patients include adult onset (2nd-6th decade) of progressive, predominantly proximal muscle weakness that subsequently involves the upper limbs. Limitation of finger and toe flexion, scapular winging, distal muscle weakness, muscle atrophy, respiratory muscle involvement, cataract, and neurogenic changes may also be present. Muscle biopsy shows variable signs of myopathy, including degeneration, fiber size variation, necrotic fibers, and rimmed vacuoles. \n\nEvidence supporting this gene-disease relationship includes case level, segregation, and experimental data. Three variants, all missense, reported in 10 probands from six publications and two abstracts are included in this curation (PMID: 24647604, 30604053, 31267206, 32407983, 32904822, 38982518; https://doi.org/10.1016/j.nmd.2023.07.197, https://doi.org/10.1016/j.nmd.2023.07.196). The two patients reported in abstracts could not be entered into the GCI but were awarded 1.0 and 0.1 pt, for a total of 9.1 points for variant-level data. In all but one patient, one of two recurrent missense changes at the same amino acid residue was identified, with three patients having p.(Asp378Asn) and six having p.(Asp378His). Functional studies have shown that these variants result in increased aggregation kinetics but disrupted fibrillation, reduced overall HNRNPDL protein expression but increased insolubility, and increased propensity for the protein to form stress granules (PMID: 31995753, 36646699; https://doi.org/10.1016/j.nmd.2023.07.197). The variant reported in the last patient, p.(Gly373Arg) (https://doi.org/10.1016/j.nmd.2023.07.196), was located nearby, consistent with a mutational hotspot. Given the limited number of variants reported, additional caution may be warranted when interpreting variants outside this region without functional support. Variants also segregated with disease in at least 24 additional affected family members (3 pts). The GCEP knows of two additional families with the p.(Asp378His) variant who have not been published, but the maximum for genetic evidence (12 pts) has been reached. The GCEP is also aware of a homozygous variant in this gene being reported in association with a consistent phenotype (https://doi.org/10.1016/j.nmd.2023.07.197); this alternative inheritance pattern will be evaluated in the future as additional evidence accumulates.\n \nThe mechanism of disease is not well understood but may involve toxic gain of function. As an RNA binding protein containing a prion-like domain, *HNRNPDL* shares a biochemical function with other genes associated with neuromuscular disease phenotypes, such as *TARDBP*, *FUS*, *TAF15*, *EWSR1*, *TIA1*, *MATR3*, *HNRNPA1*, and *HNRNPA2B1* (PMID: 32292882). In some of these genes, missense variants also affect Asp residues in the prion-like domain. Drosophila models expressing human WT or mutant (Asp378Asn or Asp378His) HNRNPDL isoform 2 in muscle show mild muscle degeneration and disorganization, recapitulating the myopathic features observed in patient skeletal muscle (PMID:  31995753). Morpholino-mediated knockdown in zebrafish has also been reported to result in disorganized muscle fibers (PMID: 24647604), but the GCEP opted not to score this model due to a mismatch with the proposed mechanism of disease and insufficient demonstration of specificity. \n\nIn summary, there is definitive evidence to support the relationship between *HNRNPDL* and autosomal dominant limb girdle muscular dystrophy (12 pts genetic evidence + 1.5 pts experimental evidence, for a total of 13.5 pts). This relationship has been repeatedly demonstrated in both the research and clinical diagnostic settings and has been upheld over time. This classification was approved by the ClinGen Muscular Dystrophies and Myopathies (MDM) GCEP on January 14, 2025 (SOP Version 11). \n\nThis gene-disease pair was originally evaluated by the MDM GCEP (formerly LGMD VCEP) in January 2020. Following re-evaluation, the classification was upgraded from Moderate to Definitive due to additional reported cases and re-evaluation of variant impact on gene function and existing experimental data. ","*HNRNPDL* belongs to the subfamily of ubiquitously expressed heterogeneous nuclear ribonucleoproteins and encodes the protein heterogeneous nuclear ribonucleoprotein D like. Ribonucleoproteins bind to pre-mRNA and are involved in splicing and nuclear export. The *HNRNPDL* gene contains nine exons and eight introns, and three isoforms are produced by alternate splicing. The domain content of these isoforms differs, and they show distinct subcellular localization and properties relating to solubility, propensity to aggregation, and phase separation (PMID: 31995753). Isoform 2, which is prone to aggregation due to the loss of the N-terminal intrinsically disordered region (IDR) but retention of the C-terminal IDR, or prion-like domain, is most highly expressed in tissues. *HNRNPDL* was first reported in relation to autosomal dominant limb girdle muscular dystrophy (LGMD; includes LGMD1G/LGMDD3) in 2014 (Vieira et al, PMID: 24647604), although linkage analysis implicated the locus in 2004 (PMID: 15367920). Features observed in patients include adult onset (2nd-6th decade) of progressive, predominantly proximal muscle weakness that subsequently involves the upper limbs. Limitation of finger and toe flexion, scapular winging, distal muscle weakness, muscle atrophy, respiratory muscle involvement, cataract, and neurogenic changes may also be present. Muscle biopsy shows variable signs of myopathy, including degeneration, fiber size variation, necrotic fibers, and rimmed vacuoles. \n\nEvidence supporting this gene-disease relationship includes case level, segregation, and experimental data. Three variants, all missense, reported in 10 probands from six publications and two abstracts are included in this curation (PMID: 24647604, 30604053, 31267206, 32407983, 32904822, 38982518; [https://doi.org/10.1016/j.nmd.2023.07.197] https://doi.org/10.1016/j.nmd.2023.07.197, [https://doi.org/10.1016/j.nmd.2023.07.196] https://doi.org/10.1016/j.nmd.2023.07.196). The two patients reported in abstracts could not be entered into the GCI but were awarded 1.0 and 0.1 pt, for a total of 9.1 points for variant-level data. In all but one patient, one of two recurrent missense changes at the same amino acid residue was identified, with three patients having p.(Asp378Asn) and six having p.(Asp378His). Functional studies have shown that these variants result in increased aggregation kinetics but disrupted fibrillation, reduced overall HNRNPDL protein expression but increased insolubility, and increased propensity for the protein to form stress granules (PMID: 31995753, 36646699; [https://doi.org/10.1016/j.nmd.2023.07.197] https://doi.org/10.1016/j.nmd.2023.07.197). The variant reported in the last patient, p.(Gly373Arg) ([https://doi.org/10.1016/j.nmd.2023.07.196)] https://doi.org/10.1016/j.nmd.2023.07.196, was located nearby, consistent with a mutational hotspot. Given the limited number of variants reported, additional caution may be warranted when interpreting variants outside this region without functional support. Variants also segregated with disease in at least 24 additional affected family members (3 pts). The GCEP knows of two additional families with the p.(Asp378His) variant who have not been published, but the maximum for genetic evidence (12 pts) has been reached. The GCEP is also aware of a homozygous variant in this gene being reported in association with a consistent phenotype ([https://doi.org/10.1016/j.nmd.2023.07.197] https://doi.org/10.1016/j.nmd.2023.07.197); this alternative inheritance pattern will be evaluated in the future as additional evidence accumulates.\n \nThe mechanism of disease is not well understood but may involve toxic gain of function. As an RNA binding protein containing a prion-like domain, *HNRNPDL* shares a biochemical function with other genes associated with neuromuscular disease phenotypes, such as *TARDBP*, *FUS*, *TAF15*, *EWSR1*, *TIA1*, *MATR3*, *HNRNPA1*, and *HNRNPA2B1* (PMID: 32292882). In some of these genes, missense variants also affect Asp residues in the prion-like domain. Drosophila models expressing human WT or mutant (Asp378Asn or Asp378His) HNRNPDL isoform 2 in muscle show mild muscle degeneration and disorganization, recapitulating the myopathic features observed in patient skeletal muscle (PMID:  31995753). Morpholino-mediated knockdown in zebrafish has also been reported to result in disorganized muscle fibers (PMID: 24647604), but the GCEP opted not to score this model due to a mismatch with the proposed mechanism of disease and insufficient demonstration of specificity. \n\nIn summary, there is definitive evidence to support the relationship between *HNRNPDL* and autosomal dominant limb girdle muscular dystrophy (12 pts genetic evidence + 1.5 pts experimental evidence, for a total of 13.5 pts). This relationship has been repeatedly demonstrated in both the research and clinical diagnostic settings and has been upheld over time. This classification was approved by the ClinGen Muscular Dystrophies and Myopathies (MDM) GCEP on January 14, 2025 (SOP Version 11). \n\nThis gene-disease pair was originally evaluated by the MDM GCEP (formerly LGMD VCEP) in January 2020. Following re-evaluation, the classification was upgraded from Moderate to Definitive due to additional reported cases and re-evaluation of variant impact on gene function and existing experimental data. "],"dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/a0504490-d6e8-4eb3-ab5a-806f28408a1c","GCISnapshot":"https://genegraph.clinicalgenome.org/r/10c69d38-c981-4679-81ab-c656f435e1ed","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/10c69d38-c981-4679-81ab-c656f435e1ed_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10151","date":["2025-01-14T05:00:00.000Z","2025-01-14T17:00:00.000Z"],"role":"Approver"},{"id":"https://genegraph.clinicalgenome.org/r/10c69d38-c981-4679-81ab-c656f435e1ed_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10151","date":"2025-01-30T15:43:23.331Z","role":"Publisher"}],"curationReasons":["ErrorClarification"],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/10c69d38-c981-4679-81ab-c656f435e1ed_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2953821a-2967-41b9-b857-d86e0a0c1fd4","type":"EvidenceLine","dc:description":"Upgraded to reflect multiple pieces of functional evidence of gene impact and location in apparent hotspot and functionally important region. Recurrent across geographic regions so cases scored independently.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2953821a-2967-41b9-b857-d86e0a0c1fd4_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24647604","allele":{"id":"https://genegraph.clinicalgenome.org/r/9814ddc5-a67c-4cf6-b712-24553fef87a0","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_031372.4(HNRNPDL):c.1132G>A (p.Asp378Asn)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA170633"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/2953821a-2967-41b9-b857-d86e0a0c1fd4_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Mutant proteins showed faster aggregation kinetics in vitro (E. coli) but altered fibrillation, resulting in smaller, fewer, and less-ordered amyloid fibrils as compared to WT expression (Batlle et al. 2020, PMID: 31995753; Garcia-Pardo et al. 2023, PMID: 36646699)\nWhen expressed in Drosophila, variants resulted in reduced overall hnRNPDL protein expression but increased insolubility compared to WT expression (Batlle et al. 2020, PMID: 31995753)\nWhen expressed in cells, variants increased propensity to form stress granules at baseline and when treated with cellular stress compared to WT expression (Ibaceta et al. 2023, https://doi.org/10.1016/j.nmd.2023.07.197)\nResidues 226-276, including Asp259 (equivalent to location of patient variants, Asp378), form the highly hydrophilic fibril core. (Garcia-Pardo et al. 2023, PMID: 36646699)\n","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/4fdd16d4-a0b4-4e06-81e8-46aa3b5cad94","type":"EvidenceLine","dc:description":"Upgraded to reflect multiple pieces of functional evidence of gene impact and location in apparent hotspot and functionally important region. Recurrent across geographic regions so cases scored independently.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4fdd16d4-a0b4-4e06-81e8-46aa3b5cad94_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31267206","allele":{"id":"https://genegraph.clinicalgenome.org/r/28a4dca7-c329-4bb5-a797-6eb837ced00c","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_031372.4(HNRNPDL):c.1132G>C (p.Asp378His)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA170634"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/4fdd16d4-a0b4-4e06-81e8-46aa3b5cad94_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Mutant proteins showed faster aggregation kinetics in vitro (E. coli) but altered fibrillation, resulting in smaller, fewer, and less-ordered amyloid fibrils as compared to WT expression (Batlle et al. 2020, PMID: 31995753; Garcia-Pardo et al. 2023, PMID: 36646699)\nWhen expressed in Drosophila, variants resulted in reduced overall hnRNPDL protein expression but increased insolubility compared to WT expression (Batlle et al. 2020, PMID: 31995753)\nWhen expressed in cells, variants increased propensity to form stress granules at baseline and when treated with cellular stress compared to WT expression (Ibaceta et al. 2023, https://doi.org/10.1016/j.nmd.2023.07.197)","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/28f8ab67-a32f-4085-8066-9370be01005f","type":"EvidenceLine","dc:description":"Upgraded to reflect multiple pieces of functional evidence of gene impact and location in apparent hotspot and functionally important region. Recurrent across geographic regions so cases scored independently.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/28f8ab67-a32f-4085-8066-9370be01005f_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24647604","allele":{"id":"https://genegraph.clinicalgenome.org/r/28a4dca7-c329-4bb5-a797-6eb837ced00c"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/28f8ab67-a32f-4085-8066-9370be01005f_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Mutant proteins showed faster aggregation kinetics in vitro (E. coli) but altered fibrillation, resulting in smaller, fewer, and less-ordered amyloid fibrils as compared to WT expression (Batlle et al. 2020, PMID: 31995753; Garcia-Pardo et al. 2023, PMID: 36646699)\nWhen expressed in Drosophila, variants resulted in reduced overall hnRNPDL protein expression but increased insolubility compared to WT expression (Batlle et al. 2020, PMID: 31995753)\nWhen expressed in cells, variants increased propensity to form stress granules at baseline and when treated with cellular stress compared to WT expression (Ibaceta et al. 2023, https://doi.org/10.1016/j.nmd.2023.07.197)","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/cd79396b-da00-472a-879c-b39f58b1d69c","type":"EvidenceLine","dc:description":"Upgraded to reflect multiple pieces of functional evidence of gene impact and location in apparent hotspot and functionally important region. Recurrent across geographic regions so cases scored independently.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/cd79396b-da00-472a-879c-b39f58b1d69c_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32904822","allele":{"id":"https://genegraph.clinicalgenome.org/r/9814ddc5-a67c-4cf6-b712-24553fef87a0"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/cd79396b-da00-472a-879c-b39f58b1d69c_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Mutant proteins showed faster aggregation kinetics in vitro (E. coli) but altered fibrillation, resulting in smaller, fewer, and less-ordered amyloid fibrils as compared to WT expression (Batlle et al. 2020, PMID: 31995753; Garcia-Pardo et al. 2023, PMID: 36646699)\nWhen expressed in Drosophila, variants resulted in reduced overall hnRNPDL protein expression but increased insolubility compared to WT expression (Batlle et al. 2020, PMID: 31995753)\nWhen expressed in cells, variants increased propensity to form stress granules at baseline and when treated with cellular stress compared to WT expression (Ibaceta et al. 2023, https://doi.org/10.1016/j.nmd.2023.07.197)","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/564007a7-b84a-4006-8d1d-a0d95e48756e","type":"EvidenceLine","dc:description":"Upon re-evaluation 14 Jan. 2025, the GCEP opted not to score this case as it was not reported in the paper and the information was obtained via communication with the MYOSEQ study authors. ","calculatedScore":0.5,"direction":"Inconclusive","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/564007a7-b84a-4006-8d1d-a0d95e48756e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32528171","allele":{"id":"https://genegraph.clinicalgenome.org/r/28a4dca7-c329-4bb5-a797-6eb837ced00c"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/564007a7-b84a-4006-8d1d-a0d95e48756e_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Mutant proteins showed faster aggregation kinetics in vitro (E. coli) but altered fibrillation, resulting in smaller, fewer, and less-ordered amyloid fibrils as compared to WT expression (Batlle et al. 2020, PMID: 31995753; Garcia-Pardo et al. 2023, PMID: 36646699)\nWhen expressed in Drosophila, variants resulted in reduced overall hnRNPDL protein expression but increased insolubility compared to WT expression (Batlle et al. 2020, PMID: 31995753)\nWhen expressed in cells, variants increased propensity to form stress granules at baseline and when treated with cellular stress compared to WT expression (Ibaceta et al. 2023, https://doi.org/10.1016/j.nmd.2023.07.197)","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/a6be54e6-3023-4d0e-abdf-515d0e2e05a5","type":"EvidenceLine","dc:description":"Upgraded to reflect multiple pieces of functional evidence of gene impact and location in apparent hotspot and functionally important region. Recurrent across geographic regions so cases scored independently.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a6be54e6-3023-4d0e-abdf-515d0e2e05a5_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32407983","allele":{"id":"https://genegraph.clinicalgenome.org/r/28a4dca7-c329-4bb5-a797-6eb837ced00c"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/a6be54e6-3023-4d0e-abdf-515d0e2e05a5_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Mutant proteins showed faster aggregation kinetics in vitro (E. coli) but altered fibrillation, resulting in smaller, fewer, and less-ordered amyloid fibrils as compared to WT expression (Batlle et al. 2020, PMID: 31995753; Garcia-Pardo et al. 2023, PMID: 36646699)\nWhen expressed in Drosophila, variants resulted in reduced overall hnRNPDL protein expression but increased insolubility compared to WT expression (Batlle et al. 2020, PMID: 31995753)\nWhen expressed in cells, variants increased propensity to form stress granules at baseline and when treated with cellular stress compared to WT expression (Ibaceta et al. 2023, https://doi.org/10.1016/j.nmd.2023.07.197)","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/5daed4e2-16f0-4893-a6d2-765aaf36a5c1","type":"EvidenceLine","dc:description":"Upgraded to reflect multiple pieces of functional evidence of gene impact and location in apparent hotspot and functionally important region. Recurrent across geographic regions so cases scored independently.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5daed4e2-16f0-4893-a6d2-765aaf36a5c1_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/38982518","allele":{"id":"https://genegraph.clinicalgenome.org/r/28a4dca7-c329-4bb5-a797-6eb837ced00c"},"alleleOrigin":{"id":"cg:AlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/5daed4e2-16f0-4893-a6d2-765aaf36a5c1_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Mutant proteins showed faster aggregation kinetics in vitro (E. coli) but altered fibrillation, resulting in smaller, fewer, and less-ordered amyloid fibrils as compared to WT expression (Batlle et al. 2020, PMID: 31995753; Garcia-Pardo et al. 2023, PMID: 36646699)\nWhen expressed in Drosophila, variants resulted in reduced overall hnRNPDL protein expression but increased insolubility compared to WT expression (Batlle et al. 2020, PMID: 31995753)\nWhen expressed in cells, variants increased propensity to form stress granules at baseline and when treated with cellular stress compared to WT expression (Ibaceta et al. 2023, https://doi.org/10.1016/j.nmd.2023.07.197)","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/34ba4962-48e8-4095-9a94-403b0c5184a9","type":"EvidenceLine","dc:description":"The variant is noted to have been observed in 2 alleles and was confirmed to be homozygous through direct communication with the study authors. The proband's parents and sibling were heterozygous and unaffected. Upon re-evaluation 14 Jan. 2025, the GCEP opted not to score this case given it does not provide support for autosomal dominant inheritance. The same proband is described in Ibaceta et al. 2023, https://doi.org/10.1016/j.nmd.2023.07.197.","calculatedScore":0.5,"direction":"Inconclusive","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/34ba4962-48e8-4095-9a94-403b0c5184a9_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32528171","allele":{"id":"https://genegraph.clinicalgenome.org/r/26e82781-fe96-4021-bbc3-70334a1b4c3c","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_031372.4(HNRNPDL):c.1130A>G (p.Tyr377Cys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA357168676"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/34ba4962-48e8-4095-9a94-403b0c5184a9_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"When expressed in cells, this variant increased propensity to form stress granules at baseline and when treated with cellular stress compared to WT expression, similar to the effects of the Asp378His and Asp378Asn variants. (Ibaceta et al. 2023, https://doi.org/10.1016/j.nmd.2023.07.197)","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/018a40e6-622f-405a-abd5-6f1dab188f09","type":"EvidenceLine","dc:description":"Upgraded to reflect multiple pieces of functional evidence of gene impact and location in apparent hotspot and functionally important region. Recurrent across geographic regions so cases scored independently.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/018a40e6-622f-405a-abd5-6f1dab188f09_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31267206","allele":{"id":"https://genegraph.clinicalgenome.org/r/28a4dca7-c329-4bb5-a797-6eb837ced00c"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/018a40e6-622f-405a-abd5-6f1dab188f09_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Mutant proteins showed faster aggregation kinetics in vitro (E. coli) but altered fibrillation, resulting in smaller, fewer, and less-ordered amyloid fibrils as compared to WT expression (Batlle et al. 2020, PMID: 31995753; Garcia-Pardo et al. 2023, PMID: 36646699)\nWhen expressed in Drosophila, variants resulted in reduced overall hnRNPDL protein expression but increased insolubility compared to WT expression (Batlle et al. 2020, PMID: 31995753)\nWhen expressed in cells, variants increased propensity to form stress granules at baseline and when treated with cellular stress compared to WT expression (Ibaceta et al. 2023, https://doi.org/10.1016/j.nmd.2023.07.197)","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/813aaa93-86d8-4413-8ef6-ddb8a1fac0d4","type":"EvidenceLine","dc:description":"\nUpgraded to reflect multiple pieces of functional evidence of gene impact and location in apparent hotspot and functionally important region. Recurrent across geographic regions so cases scored independently.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/813aaa93-86d8-4413-8ef6-ddb8a1fac0d4_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30604053","allele":{"id":"https://genegraph.clinicalgenome.org/r/9814ddc5-a67c-4cf6-b712-24553fef87a0"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"No","zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/813aaa93-86d8-4413-8ef6-ddb8a1fac0d4_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Mutant proteins showed faster aggregation kinetics in vitro (E. coli) but altered fibrillation, resulting in smaller, fewer, and less-ordered amyloid fibrils as compared to WT expression (Batlle et al. 2020, PMID: 31995753; Garcia-Pardo et al. 2023, PMID: 36646699)\nWhen expressed in Drosophila, variants resulted in reduced overall hnRNPDL protein expression but increased insolubility compared to WT expression (Batlle et al. 2020, PMID: 31995753)\nWhen expressed in cells, variants increased propensity to form stress granules at baseline and when treated with cellular stress compared to WT expression (Ibaceta et al. 2023, https://doi.org/10.1016/j.nmd.2023.07.197)","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/10c69d38-c981-4679-81ab-c656f435e1ed_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ff8cd1b3-5048-48ac-8c68-4c8e58fe8c6a_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24647604","rdfs:label":"Vieira_Uruguayan Family","family":{"id":"https://genegraph.clinicalgenome.org/r/ff8cd1b3-5048-48ac-8c68-4c8e58fe8c6a","type":"Family","rdfs:label":"Vieira_Uruguayan Family","member":{"id":"https://genegraph.clinicalgenome.org/r/db79ce82-49c6-47a6-ba96-9984f00333bb","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24647604","rdfs:label":"Vieira_Uruguayan Proband V-1","allele":{"id":"https://genegraph.clinicalgenome.org/r/28a4dca7-c329-4bb5-a797-6eb837ced00c"},"detectionMethod":"Sanger sequencing was used to detect the variant after negative panel test (not including HNRNPDL)","firstTestingMethod":"Sanger sequencing","phenotypes":["obo:HP_0003325","obo:HP_0031177","obo:HP_0003581","obo:HP_0003701","obo:HP_0008116","obo:HP_0008956"],"previousTesting":false,"secondTestingMethod":"Next generation sequencing panels","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/28f8ab67-a32f-4085-8066-9370be01005f_variant_evidence_item"}}},"meetsInclusionCriteria":true,"phenotypePositiveAllelePositive":9,"phenotypes":["obo:HP_0008956","obo:HP_0031177","obo:HP_0003701","obo:HP_0003325","obo:HP_0003581","obo:HP_0008116"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/db79ce82-49c6-47a6-ba96-9984f00333bb"},"publishedLodScore":4.8,"sequencingMethod":{"id":"cg:AllGenesSequencing"}},{"id":"https://genegraph.clinicalgenome.org/r/7006a7e2-fee1-49b8-bc07-69b8a1d2a47f_proband_segregation","type":"FamilyCosegregation","dc:description":"Not enough segregations","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31267206","rdfs:label":"Berardo_Family B","estimatedLodScore":0.3,"family":{"id":"https://genegraph.clinicalgenome.org/r/7006a7e2-fee1-49b8-bc07-69b8a1d2a47f","type":"Family","rdfs:label":"Berardo_Family B","member":{"id":"https://genegraph.clinicalgenome.org/r/43a11b45-58b6-4237-9688-675765bd5237","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31267206","rdfs:label":"Berardo_Proband FB.III-1","ageType":"AgeAtReport","ageUnit":"Years","ageValue":46,"allele":{"id":"https://genegraph.clinicalgenome.org/r/28a4dca7-c329-4bb5-a797-6eb837ced00c"},"detectionMethod":"Exome sequencing on the proband identified the variant.","firstTestingMethod":"Exome sequencing","phenotypeFreeText":"Onset at 41y. Prominent atrophy of vastus lateralis and medialis and compromise of hip adduction and abduction. Preservation of rectus femoris and lower leg muscle strength were preserved.","phenotypes":["obo:HP_0008956","obo:HP_0002527","obo:HP_0003547","obo:HP_0003691","obo:HP_0009023","obo:HP_0003749","obo:HP_0008981","obo:HP_0003198"],"previousTesting":true,"previousTestingDescription":"CK levels: 862 IU/L (nv >150 IU/L). Scarce rimmed vacuoles, slight subsarcolemmal increase in oxidative activity, isolated atrophic fibres revealed on IHC. Clear autophagic material and filamentous structures seen on electron microscopy on muscle biopsy. Thigh muscle MRI showed severe fatty infiltration of all vastus, sartorius, adductor magnus muscles with realative sparing of gracilis, biceps femoris, semitendinosus and semimembranosus muscles. Preservation of rectus femoris and adductor longus with hypertrophy of rectus femoris noted.","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/018a40e6-622f-405a-abd5-6f1dab188f09_variant_evidence_item"}}},"meetsInclusionCriteria":false,"phenotypePositiveAllelePositive":2,"phenotypes":["obo:HP_0008994","obo:HP_0003323"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/43a11b45-58b6-4237-9688-675765bd5237"}},{"id":"https://genegraph.clinicalgenome.org/r/e2dee657-f4e2-46b2-9dd1-4df9b2b031f1_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24647604","rdfs:label":"Vieira_Brazilian Family","family":{"id":"https://genegraph.clinicalgenome.org/r/e2dee657-f4e2-46b2-9dd1-4df9b2b031f1","type":"Family","rdfs:label":"Vieira_Brazilian Family","member":{"id":"https://genegraph.clinicalgenome.org/r/23846c9c-1d81-4404-90fc-1783a9a30225","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24647604","rdfs:label":"Vieira_Brazilian Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":52,"allele":{"id":"https://genegraph.clinicalgenome.org/r/9814ddc5-a67c-4cf6-b712-24553fef87a0"},"detectionMethod":"Whole genome sequencing identified the variant in two affected individuals. Sanger sequencing was used to detect the variant in additional family members.","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"Proband walks with a cane.","phenotypes":["obo:HP_0008116","obo:HP_0008948","obo:HP_0031177","obo:HP_0008956","obo:HP_0003236"],"previousTesting":true,"previousTestingDescription":"Linkage analysis excluded 6 LGMD loci as the possible cause. Serum  CK levels were 3-fold above normal levels.","secondTestingMethod":"Whole genome shotgun sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/2953821a-2967-41b9-b857-d86e0a0c1fd4_variant_evidence_item"}}},"meetsInclusionCriteria":true,"phenotypePositiveAllelePositive":10,"phenotypes":["obo:HP_0008956","obo:HP_0008994"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/23846c9c-1d81-4404-90fc-1783a9a30225"},"publishedLodScore":6.6,"sequencingMethod":{"id":"cg:AllGenesSequencing"}},{"id":"https://genegraph.clinicalgenome.org/r/b6b82ece-bfe0-414d-92b5-e7add3f69bfc_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30604053","rdfs:label":"Sun_Chinese Family","estimatedLodScore":2.11,"family":{"id":"https://genegraph.clinicalgenome.org/r/b6b82ece-bfe0-414d-92b5-e7add3f69bfc","type":"Family","rdfs:label":"Sun_Chinese Family","member":{"id":"https://genegraph.clinicalgenome.org/r/e40ca4ec-bfec-4e1d-9e17-662a5cbe4912","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30604053","rdfs:label":"Sun_Chinese Proband III-13","ageType":"AgeAtReport","ageUnit":"Years","ageValue":52,"allele":{"id":"https://genegraph.clinicalgenome.org/r/9814ddc5-a67c-4cf6-b712-24553fef87a0"},"detectionMethod":"The variant was identified by WES and validated by Sanger sequencing.","firstTestingMethod":"Exome sequencing","phenotypeFreeText":"MRC grading fro muscle strength: Deltoid: 4L/4R, Biceps: 4L/4+R, Triceps: 4, Flexor digitorum profundus: 5, Quadriceps: 4L/4+R, Tibialis anterior: 5, Gastrocnemius: 5","phenotypes":["obo:HP_0008948","obo:HP_0003323","obo:HP_0003547","obo:HP_0003198","obo:HP_0005978","obo:HP_0008956","obo:HP_0000518","obo:HP_0002359"],"previousTesting":false,"previousTestingDescription":"CBC, electrolytes, BUN, creatine, aspartate aminotransferase, alanine aminotransferase, thyroxine, TSH, sedimentation rate and CRP were normal.","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/813aaa93-86d8-4413-8ef6-ddb8a1fac0d4_variant_evidence_item"}}},"meetsInclusionCriteria":true,"phenotypePositiveAllelePositive":5,"phenotypes":["obo:HP_0003323","obo:HP_0003547","obo:HP_0003749"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/e40ca4ec-bfec-4e1d-9e17-662a5cbe4912"},"sequencingMethod":{"id":"cg:AllGenesSequencing"}},{"id":"https://genegraph.clinicalgenome.org/r/97e74ffe-b094-4d7f-8a7f-ac6cc8e9ccc8_proband_segregation","type":"FamilyCosegregation","dc:description":"Exome sequencing performed on II-6 and II-9","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31267206","rdfs:label":"Berardo_Family A","estimatedLodScore":1.81,"family":{"id":"https://genegraph.clinicalgenome.org/r/97e74ffe-b094-4d7f-8a7f-ac6cc8e9ccc8","type":"Family","rdfs:label":"Berardo_Family A","member":{"id":"https://genegraph.clinicalgenome.org/r/c364a0bd-e47e-42cb-9734-bb73ee303e29","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31267206","rdfs:label":"Berardo_Proband FA.III-1","ageType":"AgeAtReport","ageUnit":"Years","ageValue":56,"allele":{"id":"https://genegraph.clinicalgenome.org/r/28a4dca7-c329-4bb5-a797-6eb837ced00c"},"detectionMethod":"Exome sequencing was performed on a few affected members of the family and validated by Sanger sequencing.","firstTestingMethod":"Exome sequencing","phenotypeFreeText":"Proband developed asymmetric distal lower limb weakness from the age of 38, unable to walk on heels. At the time of reporting, he was unable to raise his arms and walked with a cane.","phenotypes":["obo:HP_0008994","obo:HP_0009050","obo:HP_0003547","obo:HP_0031177","obo:HP_0009053","obo:HP_0003236","obo:HP_0008116","obo:HP_0002359","obo:HP_0003701","obo:HP_0003691"],"previousTesting":true,"previousTestingDescription":"CK levels ranged between 677 and 1800 IU/L (nv = 55-170 IU/L). Numerous rimmed vacuoles, cytoplasmic bodies and atrophic fibers seen on IHC. Abundant autophagic changes, cytoplasmic bodies, myofibrillar degeneration and filamentous bundles of Z-disc origin observed on electron microscopy on muscle biopsy.","secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/4fdd16d4-a0b4-4e06-81e8-46aa3b5cad94_variant_evidence_item"}}},"meetsInclusionCriteria":true,"phenotypePositiveAllelePositive":4,"phenotypes":["obo:HP_0008956","obo:HP_0003691"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/c364a0bd-e47e-42cb-9734-bb73ee303e29"},"sequencingMethod":{"id":"cg:AllGenesSequencing"}}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":3}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":11},{"id":"https://genegraph.clinicalgenome.org/r/10c69d38-c981-4679-81ab-c656f435e1ed_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/10c69d38-c981-4679-81ab-c656f435e1ed_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c69838d8-1df4-415e-87c0-4f6459bc76e8","type":"EvidenceLine","dc:description":"As an RNA binding protein containing a prion-like domain, shares a biochemical function shared with other genes associated with neuromuscular disease phenotypes and is involved in regulation of muscle development and function ","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6180f904-961d-48f9-b6fa-419fe0fa7650","type":"Finding","dc:description":"hnRNPDL is an RNA binding protein (RBP) involved in mRNA biogenesis that contains a prion-like domain (PrLD). RBP with PrLD are involved in multiple steps of RNA metabolism and regulate muscular development and function. Variants in RBPs with PrLDs, including TDP-43, FUS, TAF15, EWSR1, TIA1, MATR3, HNRNPA1, and HNRNPA2B1, have been connected via pathology and genetics to several neurodegenerative and neuromuscular diseases, including ALS, FTD, myopathy, muscular dystrophy, inclusion body myositis, and multisystem proteinopathy. More specifically, variants in HNRNPA1 and HNRNPA2B1 involving the replacement of a single Asp residue in the PrLD have been reported, as in hnRNPDL. However, these mutations increase protein aggregation and result in the formation of cytoplasmic inclusions and are associated with a multi-system proteinopathy affecting muscle, brain, motor neurons, and bone (Kim et al., 2013; PMID: 23455423). However, variants in HNRNPA1 with low propensity to fibrillation cause vacuolar rimmed myopathy, which is histologically similar to that associated with hnRNPDL. \n","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32292882","rdfs:label":"RBP with PrLD ","demonstrates":{"id":"cg:BiochemicalFunctionA"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/10c69d38-c981-4679-81ab-c656f435e1ed_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7bf04a79-9291-41a2-90a8-dd199e89ad88","type":"EvidenceLine","dc:description":"Upon review Jan. 14, 2025, the GCEP opted not to score this model based on the following rationale: \nUsed a control MO at lowest dosage rather than re-expression of the WT allele to demonstrate specificity of the observed effects.\nExperimental manipulation (i.e., knockdown) is not a particularly good match for the clustered missense variants reported in patients. \nDisease mechanism currently not well defined but doesnâ€™t seem likely to be straightforward LOF/haploinsufficiency given variants reported and only moderate LOF constraint (LOEUF 0.57).\n","calculatedScore":2,"direction":"Inconclusive","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/81753b7d-8c98-4b2c-b4d9-12104e81afe2","type":"Finding","dc:description":"An antisense oligonucleotide morpholino targeting th etranslation start site of hnrnpdl was used to knockdown its expression. Body shape defects or twisted tails, restricted and uncoordinated movements were seen in hnrnpdl morphants, consistent with myopathy. IHC revealed abnormalities in the chevron pattern in myofibers, which were also disorganized.\n\nMutation in hrp1 (the yeast ortholog of HNRNPDL) in yeast reveal pronounced effects on protein levels and cellular localization and reorganization of proteins involved in RNA-processing pathways.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24647604","rdfs:label":"Vieira_Zebrafish","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/105c269d-769b-42f7-8e7d-50c777840896","type":"EvidenceLine","dc:description":"The models suggest that overexpression of WT or mutant human HNRNPDL isoform 2 results in myopathy in skeletal muscle, consistent with the phenotype observed in patients and the GOF mechanism proposed for reported variants.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c13d7fbd-ad29-4f06-9a77-b34faec6b9d6","type":"Finding","dc:description":"Expressed a single copy of human WT or mutant HNRNPDL isoform 2 (DL2) (Asn or His variant) in Drosophila muscle using UAS/GAL4 system with an Mhc-Gal4 driver. Expression of mutant DL2 resulted in mild muscle fiber degeneration and disorganization with no visible protein inclusions, which is similar to the signs of myopathy observed in patient skeletal muscle. There was no description of a movement phenotype in the flies. Expression of WT DL2 led to similar effects, suggesting the muscle phenotype is not variant-specific and may be a consequence of overexpression of human DL2.\n","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31995753","rdfs:label":"Batlle 2020 Drosophila models","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":1.5}],"evidenceStrength":"Definitive","sequence":9887,"specifiedBy":"GeneValidityCriteria11","strengthScore":12.5,"subject":{"id":"https://genegraph.clinicalgenome.org/r/siq1WfUc42M","type":"GeneValidityProposition","disease":"obo:MONDO_0015151","gene":"hgnc:5037","modeOfInheritance":"obo:HP_0000006"},"version":"3.1","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_10c69d38-c981-4679-81ab-c656f435e1ed-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}